Nama's AI scorecard currently rates Pulse Biosciences Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PLSE report earnings?

Pulse Biosciences's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.25.

What is the PLSE price target?

The median analyst price target from 6 analysts is $59.00, with a range of $55.00 – $73.00.

Is PLSE Shariah compliant?

Nama's AAOIFI-style screen reads Pulse Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Pulse Biosciences (PLSE)

Healthcare · Medical Instruments Supplies · NASDAQ

Pulse Biosciences (PLSE) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $3.80B and a free-cash-flow yield of -1.5%. Nama's AI scorecard rates it Sell, 3.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +212.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-9.5%

How far the last close sits under the highest price of the past five years.

Market cap	$3.80B
Trailing P/E	—
Price / book	37.8
Price / sales	2664.5
FCF yield	-1.5%
Dividend yield	—
Gross margin	0.2%
Operating margin	-7007.8%
Net margin	-6755.8%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	-20.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

PLSE earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.25). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.24	-$0.29	+17.2%	—
Q2 2026	Aug 6, 2026	-$0.28	-$0.28	+0.0%	$434,000
Q1 2026	May 4, 2026	-$0.24	-$0.22	-9.1%	$401,000
Q4 2025	Feb 19, 2026	-$0.18	-$0.21	+14.3%	$264,000

PLSE analyst price target

Median target $59.00 from 6 analysts, ranging $55.00 – $73.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live PLSE data on Nama Insights →

PLSE FAQ

Is PLSE a buy?: Nama's AI scorecard currently rates Pulse Biosciences Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PLSE report earnings?: Pulse Biosciences's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.25.
What is the PLSE price target?: The median analyst price target from 6 analysts is $59.00, with a range of $55.00 – $73.00.
Is PLSE Shariah compliant?: Nama's AAOIFI-style screen reads Pulse Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.